CANF: Can-Fite BioPharma Ltd. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
9 institutions reported holding $150K of Can-Fite BioPharma Ltd. on Form 13F (15 the quarter before). 0 opened a new position and 6 sold out. Shares held by institutions: -53%.
| Largest holders | Shares | Value |
|---|---|---|
| CITADEL ADVISORS LLC | 32,533 | $97K |
| RHUMBLINE ADVISERS | 17,433 | $52K |
| BFC Planning, Inc. | 250 | $742 |
| FIFTH THIRD BANCORP | 150 | $446 |
| WELLS FARGO & COMPANY/MN | 59 | $175 |
| Activest Wealth Management | 10 | $30 |
| TD Waterhouse Canada Inc. | 1 | $4 |
| MORGAN STANLEY | 1 | $3 |
| Avion Wealth | 5 | - |
Clinical trial readouts
1 Phase 2 or 3 trials by Can-Fite BioPharma Ltd. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-08-31 (est.) | Piclidenoson | Lowe Syndrome | Phase 2 | 5 | Not yet recruiting | NCT07410455 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.